MAPT and Alzheimer disease: The cross-sectional cohort included a total of 668 individuals, while in the longitudinal study, a subset of 49 A + T + N + patients with AD or aMCI (male: 46.9%, age at onset: 68.9 ± 8.6 years, CSF Aβ42: 358.2 ± 140.8 pg/ml, CSF Aβ40: 7907.9 ± 3814.8 pg/ml, CSF Aβ42/40: 0.05 ± 0.01 CSF t-tau: 144.2 ± 29.4 pg/ml, CSF p-tau: 567.3 ± 212.2 pg/ml) underwent cognitive assessments and plasma biomarker detection after an average of 1-year period (1.2 ± 0.6 years).